

OKLAHOMA HEALTH CARE AUTHORITY
 AMENDED BOARD MEETING
 June 26, 2026, at 1:00 P.M.
 Oklahoma Health Care Authority
 4345 N. Lincoln Blvd.
 Oklahoma City, OK. 73105

AGENDA

Public access via Zoom:

https://www.zoomgov.com/webinar/register/WN_ot2aWaarRo-Q8J53VKsJog

Telephone: 1-669-216-1590 Webinar ID: 161 164 8639

*Please note: Since the physical address for the OHCA Board Meeting has resumed, any livestreaming option provided is provided as a courtesy. Should such livestreaming option fail or have technical issues, the OHCA Board Meeting will not be suspended or reconvened because of this failure or technical issue.

1. Call to Order / Determination of Quorum.....Marc Nuttle, Chair
2. Discussion and Vote on the March 25, 2026, OHCA Board Meeting Minutes.....Marc Nuttle, Chair
3. Chief Executive Officer Report.....Clay Bullard, Chief Executive Officer
 - a) Member Moment
4. State Medicaid Director Update.....Melissa Miller, State Medicaid Director
5. Discussion of Report from the Pharmacy.....Jeffrey Cruzan, MD
 Advisory Committee and Possible Action Regarding Chair, Pharmacy Advisory Committee
 Drug Utilization Review Board Recommendation:
 - a) Discussion and Possible Vote on Recommendations Made by the Drug Utilization Review Board Pursuant to 63 O.S. § 5030.1, § 5030.3 To Add the Following Drugs to the Utilization and Scope Prior Authorization Program under OAC 317:30-5-77.2(e):

Item:	Drug Name:	Used For:
i.	Cardamyst™ (Etripamil Nasal Spray)	Paroxysmal Supraventricular Tachycardia (PSVT)
ii.	Yutrepia™ (Treprostinil Powder for Inhalation)	Pulmonary Hypertension (PH)
iii.	Komzifti™ (Ziftomenib)	Acute Myeloid Leukemia (AML)
	Lymphir™ (Denileukin Diftitox-cxdl)	Cutaneous T-Cell Lymphoma (CTL)
	Lunsumio VELO™ (Mosunetuzumab-axgb)	Follicular Lymphoma (FL)
	Nilotinib D-Tartrate	Chronic Myeloid Leukemia (CML)
	Phyrago™ (Dasatinib)	Multiple types of Leukemia
iv.	Fesilty™ (Fibrinogen, Human-chmt)	Congenital Fibrinogen Deficiency (CFD)
v.	Waskyra™ (Etuvedidigene Autotemcel)	Wiskott-Aldrich Syndrome (WAS)
vi.	Palsonify™ (Paltusotine)	Acromegaly
	Vykat™ XR [Diazoxide Choline Extended Release (ER)]	Hyperphagia of Prader Willi Syndrome (PWS)
	Yuviwel® (Navenpegritide)	Achondroplasia
vii.	Nypozi™ (Filgrastim-txid)	Neutropenia
viii.	Tryptyr® (Acoltremon 0.003% Ophthalmic Solution)	Dry Eye Disease (DED)

ix.	Clindesse® (Clindamycin Phosphate 2% Vaginal Cream)	Bacterial Vaginosis (BV)
x.	Avgemsi™ (Gemcitabine) Emrelis™ (Telisotuzumab Vedotin-tllv) Ensacove™ (Ensartinib) Hernexeos® (Zongertinib) Hyrnuo® (Sevabertinib) Ibtrozi™ (Taletrectinib) Rybrevant Faspro™ (Amivantamab/Hyaluronidase-lpui)	Non-Small Cell Lung Cancer (NSCLC)
xi.	Voyxact® (Sibeprenlimab-szsi)	Primary Immunoglobulin A Nephropathy (IgAN)
xii.	Ityisma® (Onasemnogene A베parovec-brve)	Spinal Muscular Atrophy (SMA)
xiii.	Jascavd® (Nerandomilast)	Pulmonary Fibrosis (PF)
xiv.	Rethymic® (Allogeneic Processed Thymus Tissue-agdc)	Congenital Athymia (CA)
xv.	Eydenzelt® (Aflibercept-boay)	Age-Related Macular Degeneration (AMD)

6. Discussion of Report from thePhillip Kennedy
Compliance Advisory Committee Chair, Compliance Advisory Committee
and Possible Action

a) Discussion and Possible Vote to Approve the State Plan Amendment Rate Committee Rates pursuant to 63 O.S. Section 5006 (A)(2) under OAC 317:1-3-4:

- i. Regular Nursing Facilities Rate Increase
- ii. Acquired Immune Deficiency Syndrome (AIDS) Nursing Facilities Rate Increase
- iii. Regular Intermediate Care Facilities for Individuals with Intellectual Disabilities (ICF/IID) Rate Increase
- iv. Acute (16 Bed-or-Less) Intermediate Care Facilities for Individuals with Intellectual Disabilities (ICF/IID) Rate Increase
- v. Program of All Inclusive Care for the Elderly
- vi. Lodging & Meals Rate Change

b) Discussion and Possible Vote regarding the Authority’s ability to withstand the procurement decision made by the CEO based on the Authority’s budget and available funds pursuant to 63 O.S. Section 5006(A)(2) under OAC 317:10-1-16:

New Contracts:

- i. Automated Third-Party Verification Data
- ii. Identity Proofing / Fraud Prevention Solution
- iii. AI Document Processing for Overall Medicaid System and CEV
- iv. Mobile App for Medicaid Services
- v. Health Information Exchange
- vi. EGID Bundled Services
- vii. Non-Emergency Medical Transportation (new contract and extension)
- viii. Rural Health Transformation: PACE Expansion & Stabilization Agreement

Amendments:

- ix. Consulting Services – Rural Health Transformation PACE Technical Assistance

